Literature DB >> 3029956

Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.

H Huismans, N T van der Walt, M Cloete, B J Erasmus.   

Abstract

A method to purify the neutralization specific antigen of bluetongue virus P2 in large amounts has been developed. The purified protein is free from virus-specified or cellular contaminants and its immunological specificity has been preserved. The purification is based on the observation that protein P2 can be dissociated from the virion by treatment with monovalent or divalent salts. The salt concentration required to solubilize the outer capsid proteins is pH dependent and in general decreases with a decrease in pH. P2 purified by extraction from polyacrylamide gels does not induce immune-precipitating or neutralizing antibodies. The response against P5, on the other hand, is much less conformational dependent and P5 purified from gels readily induces P5-precipitating antibodies in rabbits. These antibodies do not neutralize the virus. Purified P2, immunoabsorbed with anticore serum to remove trace amounts of P7, was injected into sheep. An initial dose of 50 micrograms of P2 was sufficient to induce P2-precipitating antibodies as well as neutralizing and hemagglutination-inhibiting antibodies. These sheep were fully protected against challenge with a virulent strain of the same BTV serotype. Lower doses of P2 still provided a significant level of protection even though no neutralizing antibodies could be detected.

Entities:  

Mesh:

Year:  1987        PMID: 3029956     DOI: 10.1016/0042-6822(87)90326-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity.

Authors:  Mario Forzan; Christoph Wirblich; Polly Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

2.  Structural insight into African horsesickness virus infection.

Authors:  Violeta Manole; Pasi Laurinmäki; Wouter Van Wyngaardt; Christiaan A Potgieter; Isabella M Wright; Gert J Venter; Alberdina A van Dijk; B Trevor Sewell; Sarah J Butcher
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins.

Authors:  Xing Zhang; Mark Boyce; Bishnupriya Bhattacharya; Xiaokang Zhang; Stan Schein; Polly Roy; Z Hong Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-23       Impact factor: 11.205

4.  Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep.

Authors:  M A Ramakrishnan; A B Pandey; K P Singh; R Singh; S Nandi; M L Mehrotra
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

5.  VP2 is the major exposed protein on orbiviruses.

Authors:  S A Lewis; M J Grubman
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

Review 6.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

7.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

8.  In vitro phosphorylation and purification of a nonstructural protein of bluetongue virus with affinity for single-stranded RNA.

Authors:  H Huismans; A A van Dijk; A R Bauskin
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

9.  RT-PCR assays for seven serotypes of epizootic haemorrhagic disease virus & their use to type strains from the Mediterranean region and North America.

Authors:  Narender S Maan; Sushila Maan; Kyriaki Nomikou; Donna J Johnson; Mehdi El Harrak; Hafsa Madani; Hagai Yadin; Serife Incoglu; Kadir Yesilbag; Andrew B Allison; David E Stallknecht; Carrie Batten; Simon J Anthony; Peter P C Mertens
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

10.  Vaccinia virus expression of the VP7 protein of South African bluetongue virus serotype 4 and its use as an antigen in a capture ELISA.

Authors:  M Cloete; D H du Plessis; A A van Dijk; H Huismans; G J Viljoen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.